Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 3 (2018), Article ID 3:IJCPP-134, 15 pages
https://doi.org/10.15344/2456-3501/2018/134
Review Article
Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

José Ramón Azanza*, Belén Sádaba and Nieves Díez

Clinical Pharmacology Service, Clinical University of Navarra, Pamplona, Spain
Prof. José Ramón Azanza Perea, Clinical Pharmacology Service, Clinical University of Navarra, Pamplona, Spain, Tel: +34948296695, Fax: +34948296500; E-mail: jrazanza@unav.es
09 April 2017; 26 April 2018; 28 April 2018
Azanza JR, Sádaba B, Díez N (2018) Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Int J Clin Pharmacol Pharmacother 3: 134. doi: https://doi.org/10.15344/2456-3501/2018/134
© 2018 Azanza et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

There are 5 BCR/ABL tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML): bosutinib, ponatinib, imatinib, nilotinib and dasatinib. The availability of several therapeutic options raises the possibility of individualizing patient treatment. When evaluating patients’ individual pharmacological profiles, it is important to take into account the differences in the chemical structures of the drugs. Bosutinib, which has a unique interaction and safety profile, is a quinazoline, unlike the other TKIs that have a pyrimidine structure. All 5 TKIs inhibit the BCR/ABL tyrosine kinase, although only ponatinib is active against the strains expressing the T315I mutation. In addition, the 5 TKIs are generally non-selective drugs that can also inhibit other tyrosine kinases, such as cKIT or PDGFR, leading to both benefits in the treatment of some gastrointestinal tumors as well as additional adverse events. These drugs are orally administered and show moderate bioavailability, a large volume of distribution, high protein binding, and elimination after intense metabolism involving various Cytochrome P450 (CYP). They are also substrates of transport proteins and interact with inducers and inhibitors. All TKIs, except bosutinib, can inhibit the activity of transport proteins, leading to important drug interactions. As such, bosutinib is the drug with the better pharmacological profile. There is a close relationship between drug concentration and the beneficial/toxic effects of imatinib, nilotinib, and dasatinib. Therefore, plasma levels should be monitored to optimize patient treatment. Currently, there is no information for ponatinib. Overall, there is a high incidence of adverse events; although these do not usually lead to treatment discontinuation. All 5 TKIs have a similar safety profile; however, each TKI has unique adverse events. Pharmacological differences can identify the drug that is best suited to each patient, helping optimize CML therapy.


1. Introduction

Chronic myeloid leukemia (CML) is a myeloproliferative disorder produced by clonal proliferation of multipotential hematopoietic cells. It is a biphasic disease that presents a chronic early phase characterized by a massive expansion of myeloid precursor cells and mature cells that prematurely escape from the bone marrow but maintain their ability to differentiate normally. This phase is followed by an acute phase in the form of blast crisis, which can have a fatal outcome [1].

CML is characterized by the presence of the Philadelphia chromosome, due to a translocation between chromosomes 9 and 22 that forms a fusion gene of Breakpoint cluster region (BCR)/Abelson murine leukemia gene (ABL)[2].

At present, there are 5 drugs for CML that act by inhibiting tyrosine kinases (TK) including, the ABL kinase, which is involved in the genesis of this disease.

The first drug was imatinib, after which nilotinib, dasatinib, bosutinib, and ponatinib were developed. These drugs have different chemical structures and a different pharmacological profile.

This article aims to review the pharmacological characteristics of each of these drugs so that, as an expression of their strengths and weaknesses, conclusions can be drawn for clinical practice.

2. Chemical Structure

Table 1 describes the chemical structures of the 5 molecules. Bosutinib is a quinazoline [3,4], the other 4 drugs share a central pyrimidine-like structure [5-9]. Three of the drugs, imatinib, nilotinib, and posatinib are benzamides.

figure 1
Table 1: Structures, IUPAC chemical formula, and molecular weight of BCR/ABL inhibitors.

These chemical differences can partly explain the selectivity of the pharmacological effect, the different involvement in pharmacological interactions by alteration of Cytochrome P450 (CYP), and the activity of some transporter proteins. Furthermore, some of the adverse effects shared by nilotinib and ponatinib may have their origin in the presence of a trifluorophenyl in the structure of both these compounds.

3. Pharmacodynamics

The most important event in CML is a reciprocal chromosomal translocation t(9;22)(q34;q11) that occurs in stem cells. It is a translocation between the long arms of chromosomes 9 and 22 known as the Philadelphia chromosome and is present in up to 90% of patients with CML. The molecular consequence is the presence of a BCR/ABL chimeric gene on chromosome 22 and its reciprocal ABL/BCR on chromosome 9. The latter, unlike the first, does not have transcriptional activity and does not seem to have functional activity in CML development. In contrast, the BCR/ABL fusion gene is a constitutively activated TK capable of activating various transcriptional processes [10] and is found exclusively in the cytoplasm of cells forming complexes with cellular cytoskeleton proteins [11].

Increased BCR/ABL TK activity phosphorylates diverse cellular substrates that alter the process of cell differentiation and proliferation. Activated substrates include various transcription activation signals: RAS/MAPK, PI-3 kinase (PI-3K), CBL and CRKL, and the JAK-STAT and SRC pathways [12-14].

Once activated, the ABL kinases regulate signaling involved in the reorganization of the cytoskeleton vital in cell protrusion, cell migration, morphogenesis, adhesion, endocytosis and phagocytosis, as well as the regulation of cell survival and proliferation pathways [15-17]. This aberrant signaling activity can give rise to various types of tumors, including CML.

With this background it is not surprising that identifying drugs that are able to inhibit ABL kinases is a priority to control tumor evolution, including CML.

The 5 available drugs inhibit various TKs, including BCR/ABL, but with different inhibitory profiles, which can potentially explain differences in efficacy and toxicity [18]. Table 2 summarizes the in vitro activity of the different BCR/ABL TK inhibitors (TKIs), obtained in a comparative study [19].

figure 2
Table 2: Relative activity of BCR/ABL inhibitors against different tyrosine kinases (adapted from Uitdehaag[19]).

Table 2 shows that bosutinib is the only drug that does not inhibit C-KIT and that has a lower inhibition of platelet-derived growth factor (PDGFRα). These characteristics are important since the first is the membrane receptor of stem cell factor (SCF), also termed" steel factor" or "c-kit ligand", a polypeptide that activates the precursors of bone marrow blood cells and is also present in other cells.

C-KIT mutations in the interstitial cells of Cajal in the digestive tract can be key in the development of gastrointestinal stromal tumors (GIST). The C-KIT receptor is related to macrophage colony- stimulating factor (CSF-1) and to PDGF, hence inhibiting C-KIT generates myelosuppression as an adverse event. C-KIT inhibition can also lead to cutaneous adverse events because C-KIT stimulates the proliferation and migration of melanoblasts and germ cells. On the other hand PDGF has an important role in embryogenic development, cell proliferation and migration and angiogenesis.

It is also noteworthy that ponatinib is active against BCR/ABL strains that are resistant to other drugs; however, it also inhibits kinases that may be related to adverse cardiac and vascular effects.

The activity of BCR/ABL inhibitors depends on the presence of resistance mutations. It is estimated that 20-30% of patients either do not respond to initial treatment (primary resistance) or relapse after the initial response [20,21]. Resistance to imatinib and to other BCR/ABL inhibitors can also occur because of infra therapeutic drug concentrations, due to lack of compliance by the patient, inadequate doses, alterations in the activity of the isoenzymes that metabolize the inhibitors, or alterations of the transporter proteins that are involved in the pharmacokinetic process [22-25]. There are some BCR/ABL mutations that are partially or completely resistant to BCR/ABL inhibition. For example, the BCR/ABL T315I mutation is resistant to all BCR/ABL inhibitors except ponatinib [9,26,27].

4. Pharmacokinetics

From the pharmacokinetic point of view, TKIs are characterized, as noted in Table 3, by oral absorption, a wide distribution within the total volume of body water, and the elimination through CYP450 metabolism.

table 3
Table 3: Main pharmacokinetic parameters of BCR/ABL inhibitors.

4.1 Absorption

The absolute bioavailability of these drugs ranges from 14% for dasatinib to 98% for imatinib. In general, absorption is slow with the maximum plasma concentration (Cmax) occurring between 0.5 and 6 h [28-35].

There is proportionality between the Cmax and the area under the plasma concentration-time curve (AUC) with the dose administered for bosutinib, dasatinib, nilotinib and ponatinib. However, with dasatinib, the values of Cmax and AUC are higher when administered once a day compared with twice daily [36]; contrary to what happens with nilotinib [34,37].

At steady state, imatinib AUC increases 1.6-fold compared with the AUC of the first dose [38,39]. Similarly, there is an increase in Cmax at steady state for bosutinib (2-fold), nilotinib (3.8-fold), and ponatinib (1.5-fold) [32,34,40].

4.1.1 Effect of food on absorption

While the administration of bosutinib at a dose of 200 mg and 400 mg to healthy volunteers together with food, increased Cmax and AUC values by 2-fold and 1.4-fold compared with fasting administration; no differences were found in the case of dasatinib, imatinib [41] or ponatinib [42]. The incidence and severity of the adverse events with bosutinib 400 mg in fasting conditions were similar to bosutinib 600 mg administered with food, suggesting that administration with food improves tolerability [28].

Administration with a high-fat meal increases nilotinib Cmax and AUC by 112% and 82%, respectively. When nilotinib intake occurred 30 minutes or 2 hours after the meal, the increase in bioavailability was 29% and 15%, respectively [43]. Therefore it is recommended to not eat any food in the 2 hours before and in the hour after taking nilotinib, so that the bioavailability increase does not lead to increased adverse events.

4.2 Distribution

In plasma, drugs in this class are found mostly protein bound to albumin and alpha-glycoprotein; in the case of nilotinib and imatinib especially to the latter. In animal models, it has been shown that high concentrations of α1 glycoprotein may be associated with an absence of response to imatinib. The administration of intravenous clindamycin, a drug that is fixed in high proportion to α1 glycoprotein, can reduce the bioavailability of imatinib up to 2.9-fold [44,45].

The volume of distribution of these drugs exceeds the body water content [31,34,35,46,47].

Dasatinib is able to slightly cross the blood-brain barrier with a plasma concentration of 0.05-0.28 ng/ml [48]. Imatinib diffuses marginally to CSF; however, the CSF levels are up to 74-fold lower than in plasma. This reduced diffusion is probably related to the fact that these drugs are a P-glycoprotein substrate, which limits diffusion to the nervous system [34,49,50].

4.3 Elimination

All drugs in this class are metabolized before elimination. As described in Table 4, several isoenzymes of CYP450 are involved in their metabolism, with potential drug-drug interactions. Bosutinib, dasatinib, imatinib and their respective metabolites are eliminated primarily in the faeces, while urinary excretion does not exceed 5% [31,35,39,51-54].

table 4
Table 4: Metabolism and metabolite activity of BCR/ABL inhibitors.

Bosutinib has the longest elimination half-life, with mean values ranging between 32.4 and 41.2 h, while dasatinib has the shortest halflife (5.6 h) [31,32,52]. The other drugs have comparable half-lives, between 17-22 h.

4.4 Pharmacokinetics in special situations

4.4.1 Hepatic impairment

The Cmax and the AUC of bosutinib increased 2.42-fold and 2.25- fold in patients with Child Pugh cirrhosis A, 1.99-fold and 2-fold in patients with Child Pugh B, and 1.52-fold and 1.91-fold in patients with Child Pugh C. The elimination half-life was 86, 113 and 111 h in each of the grades [55]. A dose adjustment is recommended in patients with hepatic impairment since there is a potential risk of QTc prolongation. This adverse event has not been described in patients who did not have liver function abnormalities [56].

Patients with abnormal liver function may have a 50% increase in the AUC of imatinib [57] as well as is probably the case for ponatinib [35].

In general, caution is recommended when using any of these drugs in patients with hepatic insufficiency.

4.4.2 Renal impairment

In patients with several renal impairment, the AUC and Cmax of bosutinib increased by 60% and 34%, respectively; and in patients with moderate renal impairment, the increase is 35% and 28%, respectively. The dose should be adjusted if creatinine clearance is below 50 ml/min [58]. In the case of dasatinib, Cmax and AUC are reduced in patients with moderate or severe renal insufficiency. Caution and close monitoring of patients with renal impairment is recommended [31].

The AUC0-24 of imatinib at steady state increases 2.1-fold in patients with moderate renal impairment [59,60].

In the absence of data on administering ponatinib to patients with renal impairment, it is advisable to also use caution in patients with moderate and severe renal insufficiency [35].

4.4.3 Pediatrics

In children, the Cmax values of imatinib at 260 mg/m2 and 340 mg/m2 were 3.6 mg/l and 2.5 mg/L, respectively, with a Tmax of around 3.5 h. When treating children with CML, the recommended dose of imatinib is 260-300 mg/m2/day [61].

5. Interactions

The 5 drugs are metabolized, to a greater or lesser extent, through isoenzymes of CYP450 (Table 4). In addition, these drugs are substrates and at times, inhibitors of the activity of transport proteins such as P-glycoprotein and breast cancer resistance protein BCRP. Table 5 summarizes the inhibitory activity of these drugs and Table 6 details the various types of interactions.

table 5
Table 5: Inhibitory activity of CYP3A4 and transport proteins.
table 6
Table 6: Pharmacokinetic interactions of BCR/ABL inhibitors.

5.1 Effect of BCR/ABL inhibitors on CYP450 and transport proteins

5.1.1 Bosutinib

Bosutinib is a CYP3A4 substrate, but is not a substrate for any of the remaining Cytochrome P450 (CYP). Furthermore, it does it seem to have the capacity to induce or inhibit these isoenzymes.

5.1.2 Dasatinib

Dasatinib is metabolized through the CYP3A4 isoenzyme. In vitro, it is a substrate of P-glycoprotein and BCRP but it does inhibit these transporters. Dasatinib is also a substrate of the human organic cation transporter type 1 (hOCT1), although with a lower affinity than imatinib [62,63]. Dasatinib has inhibitory activity against CYP2C8, CYP3A4, CYP2C9 and CYP2A6.

5.1.3 Imatinib

Imatinib is mainly metabolised by CYP3A4, whereas CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 play a smaller role. With long-term administration, imatinib tends to inhibit its own metabolism, and CYP2C8 becomes more relevant for its metabolism [64]. Imatinib is also a substrate of hOCT1, P-glycoprotein, and BCRP, and can inhibit the activity of these two last ones. It can also competitively inhibit the metabolism of drugs that are substrates of CYP2C9, CYP2C19, CYP2D6 and CYP3A4.

5.1.4 Nilotinib

Nilotinib is metabolized through CYP3A4, and is a substrate of P-glycoproteinand BCRP. In addition, it inhibits CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, P-glycoprotein and BCRP, the latter in an important way [65]. In vitro, nilotinib has been shown to induce CYP2B6.

5.1.5 Ponatinib

Ponatinib is a CYP3A4/5 substrate and in smaller amounts is also a substrate of CYP2C8 and CYP2D6. Ponatinib is not a substrate, but it inhibits the activity of P-glycoprotein and BCRP, with reduced IC50 values. Therefore, ponatinib has the potential to increase the plasma concentrations of drugs that are substrates of these transporter proteins such as: digoxin, pravastatin, dabigatran, methotrexate, or sulfasalazine [66-74].

5.2 CYP450 interactions

As indicated, all BCR/ABL inhibitors are substrates of Cytochrome P450 (CYP); therefore, their rate of elimination can be altered by other drugs that increase or reduce the activity of these isoenzymes. In addition, dasatinib, imatinib, nilotinib, and ponatinib regulate CYP450 interaction since they can reduce the enzymatic activity of some of the isoenzymes. This characteristic is not shared by bosutinib, and is a better choice for the polymedicated patient, thereby avoiding potential drug-drug interactions.

5.2.1 Drugs that alter the metabolism of BCR/ABL inhibitors

The activity of isoenzymes can be increased (induced), except that of CYP2D6, or reduced (inhibited). With inhibition, there is a reduction in the rate of elimination of the drugs that are metabolized by the isoenzyme. Consequently, the drugs are accumulated in the body leading to an increased risk of toxicity that remains as long as the dose of the drug is not reduced. With induction, there is a reduction of the pharmacological activity of the drug because the drugs are eliminated too quickly from the body.

5.2.2 Bosutinib and dasatinib

As a CYP3A4 substrate, bosutinib experiences an increase in Cmax and AUC when combined with inhibitors of this isoenzyme, such as ketoconazole [29,75] or aprepitant [76]. On the other hand, when combining bosutinib with rifampicin, an enzyme inducer, there is a reduction in bosutinib bioavailability [30]. Similarly, concomitant administration of dasatinib and ketoconazole increased the AUC of dasatinib [77], whereas rifampicin reduced it.

5.2.3 Imatinib

All drugs that inhibit CYP3A activity may increase the bioavailability of imatinib, such as ketoconazole, levothyroxine, voriconazole or amiodarone. The same is not true for ritonavir; although it is a potent inhibitor of CYP3A4 activity, there is a compensatory mechanism of induction [78-83]. CYP3A inducers or P-glycoprotein, such as rifampin, carbamazepine, phenobarbital, phenytoin and St. John's Wort, can reduce the exposure of imatinib, potentially compromising its therapeutic activity. The administration of a single dose of rifampicin to 10 healthy volunteers reduced AUC of imatinib by 68%, along with a 24% increase in the AUC of the active metabolite [84]. Similar results were described with St. John’s Wort [85-89].

5.2.4 Nilotinib

The bioavailability of nilotinib increases when it is used in association with CYP3A4 inhibitors such as ketoconazole, which increase 3-fold the AUC of nilotinib [43]. Nilotinib intake with fruit juice can increase AUC by up to 60%. Conversely, administration of CYP3A4 inducers, such as rifampicin, reduces AUC 4.8-fold [90].

5.2.5 Ponatinib

With ponatinib, a dose reduction to 30 mg once a day is recommended when administered concomitantly with potent CYP3A4 inhibitors. When combining with ketoconazole, a CYP3A4 inhibitor, there was an increase in ponatinib’s AUC0-∞, AUC0 to last quantifiable value, and Cmax of 78%, 70%, and 47%, respectively [91]. CYP3A4 inducers can lead to a reduction in systemic exposure of ponatinib, so associated use with carbamazepine, phenobarbital or rifampicin should be avoided.

5.3 Drugs whose metabolism is altered by BCR/ABL inhibitors

5.3.1 Bosutinib

As noted, bosutinib does not alter the activity of Cytocrome P450 (CYP); however, the remaining 4 BCR/ABL TKIs do.

5.3.2 Dasatinib

Dasatinib behaves as an inhibitor of CYP450 activity so it reduces the clearance of drugs that are eliminated through this isoenzyme. This inhibitory effect may be time dependent [85]. A single dose of 100 mg of dasatinib increased the AUC and Cmax of simvastatin, a known CYP3A4 substrate, by 20% and 37%, respectively. Therefore, CYP3A4 substrates with narrow therapeutic margins (eg, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with caution in patients receiving dasatinib. There is also a potential risk of CYP2C8 inhibition, which may lead to increased concentrations of substrates of this isoenzyme such as glitazones.

5.3.3 Imatinib

Imatinib increases the intestinal absorption of cyclosporine through inhibition of P glycoprotein and the cytochrome CYP3A4, and may increase toxicity [92,93]. Co-administration of imatinib with metoprolol increased the bioavailability of metoprolol by 23% [94]. Compared with simvastatin alone, co-administration with imatinib had a 3-fold increase in the AUC of simvastatin and was associated with a 70% reduction in the clearance of simvastatin [95]. Relevant interactions have been described with other CYP3A4 substrates, such as verapamil and diltiazem, with increases in plasma concentration increase when co-administered with imatinib. Clinically relevant interactions with simvastatin, amiodarone and quinidine have been described and may also have clinical implications. Therefore, it is recommended to avoid these medications and look for safer alternatives when using imatinib [95].

Imatinib inhibits the glucuronidation of paracetamol, leading to hepatotoxicity and liver failure; so reduced doses of paracetamol are recommended when taking imatinib. As CYP2C9 substrates, acenocoumarol and phenprocoumon, have shown increased concentrations when co-administered with imatinib [96-98].

Co-adminsitration of imatinib and levothyroxine requires an increase in the dose of levothyroxine, up to 2-fold, probably due to the induction of uridine diphosphate glucuronyl transferase (UGT) activity [79,80].

Caution should be exercised when administering imatinib with other drugs that are substrates for cytochrome CYP3A, CYP2C9(warfarin), CYP2D6 (antidepressants, antipsychotics), P-glycoprotein (digoxin or dabigatran), and BCRP (mitoxantrone, topotecan and methotrexate).

5.3.4 Interactions with transport proteins

All BCR/ABL inhibitors, except bosutinib, are substrates of transport proteins such as P-glycoprotein, BCRP, or hOCT1. These proteins have the function of expelling the drug from inside the cells to prevent absorption, reduce distribution, or facilitate elimination. Therefore, concomitant administration with inhibitors or inducers of these proteins has consequences that are similar to inhibiting the isoenzymes that metabolize them: bioavailability increase or reduction.

5.3.5 Bosutinib

It has been suggested that bosutinib may be an inhibitor of P-glycoprotein, but clinical studies with dabigatran, a specific substrate of P-glycoprotein, have not shown any change in pharmacokinetics [99], allowing us to rule out the involvement of transport proteins in relevant interactions with bosutinib.

5.3.7 Dasatinib

Drugs that inhibit the activity of BCRP or CYP3A4, such as verapamil, erythromycin, clarithromycin, cyclosporine, ketoconazole, fluconazole, itraconazole and posaconazole, increase the bioavailability of dasatinib, with an increase in intracellular concentration. In turn, dasatinib can slightly inhibit transport proteins and moderately inhibit the activity of CYP3A4, changing the exposure of some drugs. Specifically, co-administration with dasatinib increases the bioavailability of simvastatin [83], and is not recommended with CYP3A4 substrates such as verapamil or diltiazem.

5.3.8 Imatinib

The administration of imatinib with a mixed inhibitor of CYP3A4 and P-glycoprotein increased plasma concentrations and also intracellular concentrations of imatinib. There is a potential risk when co-administering imatinib with verapamil, erythromycin, clarithromycin, cyclosporine, ketoconazole, fluconazole, itraconazole, or posaconazole [92,100]. Similarly, some P-glycoprotein transport inhibitors, such as intraconazole or cyclosporine, can reduce biliary excretion or modify the passage of the drug into the blood-brain barrier. The inhibition of P-glycoprotein by proton pump inhibitors (PPIs), such as pantoprazole, increases intracerebral imatinib penetration. Interactions with quinidine, ranitidine or midazolam, known inhibitors of hOCT1, can paradoxically increase plasma concentration and reduce intracellular concentration [69].

5.3.9 Ponatinib

Ponatinib is not a substrate, but it inhibits the activity of P-glycoprotein and BCRP, with reduced IC50 values. Coadministration of ponatinib can increase the plasma concentrations of drugs that are substrates of these transporter proteins such as: digoxin, pravastatin, dabigatran, methotrexate, or sulfasalazine.

5.3.10 Other interactions

The absorption of bosutinib is dose and pH-dependent. The solubility of bosutinib, like that of the other BCR/ABL TKIs, is reduced with increased gastric pH. Use of PPIs should be avoided so that the bioavailability of bosutinib is not reduced [101,102]. If pH reduction is required, H2 antacids or histamine antagonists should be used, to be taken about 2 hoursbefore or after the TKI is administered [56,103]. This interaction has also been described when dasatinib is administered with famotidine and omeprazole [104].

The use of antacids instead of H2-antagonists or PPIs should be evaluated in patients receiving treatment with bosutinib or dasatinib. The absorption of ponatinib is very dependent on solubility that is pH-dependent, so caution is recommended when using drugs that increase gastric pH.

Using imatinib with magnesium and aluminum salts is not associated with significant alterations in drug absorption [41,105].

In some clinical trials, QT prolongation was reported with dasatinib. Cardiac arrhythmias with death have been described, probably related to abnormalities of ventricular repolarization. Coadministration with drugs that produce the same effect as digoxin, quinolones, methadone or various antipsychotics may increase the risk, for which a close electrocardiographic control of the patients is recommended [106,107]. Nilotinib has also been associated with QT prolongation and with cases of sudden death, so it should not be administered to patients who are receiving drugs that produce similar symptoms, alterations in congenital QT syndrome, hypokalemia or hypomagnesemia [106,107].

6. Monitoring plasma levels

6.1 PK/PD

The relationship between pharmacokinetics and efficacy or tolerability is of great clinical interest.

6.2 Bosutinib

In a population analysis conducted with bosutinib, a relationship between the bioavailability of the drug and the incidence of diarrhea was reported, after adjusting to a maximum effect model, Emax. The probability of developing diarrhea and rash was higher among patients with higher AUC values. There was no evidence of possible relationships between exposure to the drug and the incidence of other adverse events. No relationship was found between bosutinib AUC and major cytogenetic response (MCyR) at 24 weeks [108,109].

6.3 Dasatinib

A greater and faster response was achieved with dasatinib at a dose of 100 mg than with 400 mg of imatinib once a day; however, pleural effusion was reported as an adverse event in 19% of the patients treated with dasatinib and it required treatment discontinuation in 29% of patients [110]. The efficacy of dasatinib is related to its mean concentration at steady state with optimal values of 14.16 ng/ml with 100 mg once a day and 14.32 ng/ml with 50 mg twice a day [36]. Both pleural effusion and cytogenetic response are significantly related to the plasma concentration of dasatinib, with a 1.22-fold increased risk of effusion per each 1 ng/ml increase in minimum plasma concentration (Cmin) of dasatinib [36]. Throughout the phase I and phase II studies, pleural effusion has been reported less frequently when dasatinib is administered once a day versus administration twice a day [111,112].

It has been pointed out that the Cmin of dasatinib must not exceed 2.5 ng/ml because the incidence of pleural effusion is significantly increased at higher levels. Therefore, the administration of 100 mg once daily appears to be the most reasonable dose to achieve efficacy, while reducing the incidence of adverse events [112,113].

C2 (plasma concentration at 2 hours), Cmax and AUC of dasatinib are significantly lower in patients who have a T315I mutation in BCR/ABL than in those without the mutation. Therefore, in addition to adjusting Cmin, an adjustment to C2 or Cmax is recommended, aiming that these values are at 50 ng/ml to avoid increasing the risk of developing mutations in the BCR-ABL due to low exposure to dasatinib [114]. In addition, because dasatinib Cmax values correlate with complete cytogenetic response (CCyR), some authors recommend dosing the drug to reach a Cmax or C2 of approximately 50 ng/ml and a Cmin below 2.5 ng/ml [115].

6.4 Imatinib

Imatinib has a high interpatient variability with coefficient of variation for AUC that ranges between 39% and 51%, with doses of 400 and 600 mg, respectively. There is no relationship between drug exposure, body weight, and body surface. The influence of the CYP3A polymorphism does not justify the interpatient variability, which seems to be associated with P-glycoprotein polymorphism [38]. Cmin at steady state, after administration of 400 mg a day, ranges between 100 ng/ml and 5000 ng/ml. In a Japanese population, interpatient variability has been described with a coefficient of variation between 32.8% and 62.9% [116-118]. There is also a remarkable intraindividual variability, with coefficients of variation for Cmin between 8.4% and 49.3% [119].

Several studies have indicated that patients who achieve imatinib concentrations below 1000 ng/ml have a significantly worse response when compared with those who achieve higher concentrations [120-133]. Therefore, it is currently accepted that pre-dose concentration (Cmin) with imatinib should reach at least 1000 ng/ml [119,134]. Both median overall survival and progression-free survival have been associated with higher doses of imatinib. In fact, the cumulative incidence of CCyR or major molecular response (MMR) during the first 18 months of treatment was significantly lower in patients treated with 200 mg daily, compared with those who received 300 mg or 400 mg. Therefore, in patients treated with doses of 300-400 mg who develop intolerance, the reduction of the dose to <200 mg should be avoided and treatment with other TKIs is recommended [118].

BCRP, is encoded by the ABCG2 gene (BCRP) and its fundamental function is to act as an efflux transport protein, primarily expressed in the small intestine and in the bile canaliculus [135,136]. In these locations, it is involved in the absorption, distribution and elimination of a large number of clinically relevant drugs, including imatinib. The presence of a polymorphism that affects a single nucleotide, mainly 421C/A, significantly reduces the function of this transporter protein. The need to adjust the dose in relation to the concentration achieved was significantly lower in Japanese patients who presented genotype ABCG2 421C/C than in patients with other genotypes C/A or A/A [137]. It has also been described that the clearance of imatinib in patients with a 421C/A genotype is significantly lower than that of patients with a 421C/C genotype, therefore they have higher Cmin concentrations than those with a 421C/C genotype [138,139].

BCRP also contributes to the extracellular excretion of imatinib. Therefore, the presence of polymorphic genotypes can also affect the elimination of the drug. It has been described that 54% of the patients who achieved complete molecular response (CMR) had the 421C/A allele, while 67% of the patients who did not reach CMR had the genotype 421C/C [140]. Several studies have shown an increased MMR in patients with genotype ABCG2 421C/A [139,141,142].

Imatinib, at the recommended dose of 400 mg a day, often has serious adverse events such as neutropenia, edema or skin rash, which result in poor compliance by the patient, the need to stop treatment early, and even therapeutic failure [143]. In fact, doses higher than 400 mg a day have been associated with an increased incidence of adverse events and with the need to discontinue treament with imatinib. A Cmin greater than 3180 ng/ml has been associated with a high frequency of Grade 3/4 adverse events such as neutropenia [124]. Elevated Cmin has also been associated with cutaneous rash and edema [120,124]. In fact, imatinib Cmin greater than 3000 ng/ml should be avoided.

6.5 Nilotinib

Nilotinib also has great intraindividual variability, with coefficients of variation greater than 36.4%, hence the importance of performing periodic Cmin tests [119]. Fasting administration of nilotinib at a dose of 150 mg twice a day or 200 mg twice a day leads to a faster and more important response than that of imatinib 400 mg once a day [144]. CYP3A4, 2C8, 2C9, 2D6, and UGT1A, among others, intervene in the elimination of nilotinib [65]. UGT1A is responsible for the glucuronide conjugation of bilirubin, and upon competing for the enzyme, nilotinib leads to hyperbilirubinemia [145]. High exposure to nilotinib is associated with an increased incidence of hyperbilirubinemia [146,147]. The presence of UGT1A1 polymorphisms is associated with especially high levels of bilirubin, specifically the genotype UGT1A1*28/*28 [148]. In clinical studies, the nilotinib-mediated inhibitory effect of UGT1A1 is important in patients who previously had a reduced metabolizing status for genotypes *6/*6, *6/*28, and *28/*28 [149]. In addition, in these patients, hyperbilirubinemia occurred within the first 3 weeks of treatment with nilotinib. Patients who present this risk of developing hyperbilirubinemia, should be treated with an initial dose of nilotinib of 150-200 mg twice a day, and it may even be preferable to choose another TKI due to the high risk for hyperbilirubinemia [150].

Although no significant correlation was found between the Cmin values of nilotinib at 12 months and MMR response [148], patients with nilotinib levels greater than 500 ng/ml required a significantly shorter time to reach the CCyR or MMR response [151].

The current recommendation for the optimal Cmin of nilotinib at steady state is 800 ng/ml after an initial administration of 600 mg a day [115]. At this concentration, patients with slow metabolization of UGT1A1 had a 50% incidence of Grade 3/4 hyperbilirubinemia. Therefore, for these patients the optimal concentration should be 500 ng/ml, although this can be associated with inefficiency.

6.6 Ponatinib

There is little information regarding ponatinib; although, in a phase I study a dependence of the response was observed, with the dose administered to patients with acute Ph+ lymphoblastic leukemia. Dose-dependent activity has also been described in a study performed in 43 Ph+ patients in whom a ≥50% reduction of CRKL phosphorylation, a surrogate for BCR-ABL inhibition, was observed in 67% and 94% of patients receiving doses of 8 and 15 mg respectively [40].

In a clinical trial, MCyR response at 15 months was significantly higher among patients who were between 18 and 44 years of age, or 45 and 64 years old, compared with those who were older than 65 years, with p<0.001 [152]. A relationship has been described between the incidence of adverse events and high doses of ponatinib, advanced age, duration of the disease, previous history of diabetes or ischemia, the baseline presence of neutrophilia, and high platelet numbers [153].

Table 7 summarizes the available data on monitoring plasma levels. The determination of concentrations should be performed at least at 3, 6 and 12 months.

table 7
Table 7: Monitoring plasma levels.

7. Tolerability

Establishing differences among the 5 drugs in the incidence and severity of adverse events is complicated. For example, nilotinib has a very low incidence of fluid retention, and probably has less haematological toxicity than the other TKIs; although it seems that the incidence of rash, headache, pancreatitis and cardiovascular effects is higher than that observed with imatinib. Dasatinib, on the other hand, less peripheral edema, but gastrointestinal toxicity and pleural effusion are more frequent than with imatinib. Bosutinib is characterized mainly by diarrhea, vomiting, and abdominal pain; however, there is less intensity of edema and muscle, and bone pain. Finally, ponatinib, when compared with imatinib, has a profile of important cardiovascular toxicity. In addition, it leads to higher incidence of rash, abdominal pain, headache, and pancreatitis, and lower nausea, muscle pain and diarrhea, than imatinib. In any case, the incidence of adverse events reported in clinical studies is relevant since more than 95% of patients reported some type of adverse event and about half of them needed a temporary discontinuation of the treatment or reduction of the dose. Many of these adverse events are related to hematological alterations that are resolved quickly.

Most of the adverse events occur during the first 3 months of treatment and can be handled easily, by reducing the dose or by interrupting the medication before Grade 3 or 4 toxicity appear. Surprisingly, despite the high incidence of adverse events and their apparent seriousness, there are few patients who need to permanently discontinue treatment for this reason (9-19%) [110,154,155].

Cardiovascular adverse events have been reported with imatinib. In a retrospective of 1276 patients, it was reported that 22 patients (1.7%) had heart failure, 11 of whom continued treatment after dose adjustment and heart failure management. Other TKIs have a lower cardiac toxicity profile, with cardiac events ranging from less than 1 to 4% of patients treated with dasatinib or ponatinib; while they have not been described with dasatinib or with bosutinib [156-160].

QT prolongation has been described with all TKIs, although the highest frequency has been reported with nilotinib. During the clinical development phase of nilotinib, a few cases of sudden death were reported. To evaluate potential risks, it is recommended to have an electrocardiogram (ECG) before treatment initiation, at 1 week after starting treatment, and when clinically indicated [34,37,161].

It has been suggested that treatment with nilotinib and dasatinib, compared with imatinib, carries an increased risk of arterial and venous events, as well as acute myocardial infarction [162]. It has also been described that nilotinib causes elevated blood glucose levels, hyperlipidemia, increased body mass index (BMI), as risk factors relevant to cardiovascular toxicity; although no thromboembolism events have been reported [163,164]. However, there is a higher indicence of peripheral arterial occlusive disease with nilotinib compared with imatinib, but not when compared with other controls that are not TKIs [165]. In a 6-year follow-up study, 10% of patients treated with nilotinib 300 mg twice daily were reported to have cardiovascular events, including 4% of patients with peripheral arterial occlusive events. In comparison, overall cardiovascular events were reported in 3% of patients in the control arm of imatinib [160]. Higher doses of nilotinib, 400 mg twice a day, which are approved for use in refractory or relapsed patients, report cardiovascular events in close to 16% of patients [160].

In a 5-year follow-up study of dasatinib, the incidence of ischemic alterations was 5% in the dasatinib arm compared with 2% in the imatinib arm [159]. In the case of bosutinib, the incidence of vascular arterial toxicity appears to be similar to that of imatinib [154]. However, ponatinib is associated with severe cardiovascular toxicity: 8% arterial thrombosis, 5% acute myocardial infarction, 2% peripheral arterial occlusive disease, and 2% cerebrovascular events [158]. With this drug, incidences of serious arterial thrombotic events have been reported in 5-7% of patients [152,166], and some type of cardiac or vascular toxicity has been described in 49% of patients [167]. These findings occurred in the first clinical trials with ponatinib; this drug was withdrawn from commercialization in 2013 to continue the evaluation of toxicity. Cardiovascular toxicity related to TKIs has been described by several authors [168,169].

Pulmonary complications have been reported with imatinib and nilotinib, including interstitial lung disease (ILD) in less than 1% of patients [170-173]. All TKIs can have pericardial or pleural effusions as adverse events; however, dasatinib seems to stand out, with onestudy reporting an incidence of pleural effusion during the first year of 10%, which increased to 29% by the end of the study. Overall, 20% of patients required discontinuation of dasatinib treatment due to this adverse event [159]. The frequency of pleural effusion appears to be higher with bosutinib than with imatinib. Three out of 250 patients treated with bosutinib discontinued treatment as a result of a pleural effusion, compared with none of the patients receiving imatinib [154]. Pulmonary arterial hypertension related to the use of dasatinib has been described in up to 5% of patients, some of which required discontinuation of treatment [159], although it is clinically reversible [173].

All TKIs have reported gastrointestinal adverse events, especially during the first 6 months of treatment. Imatinib, dasatinib, and bosutinib have similar rates of nausea, vomiting and abdominal pain; but, bosutinib has the highest incidence of diarrhea [154,174]. Dasatinib has reported the highest incidence of gastrointestinal hemorrhage, which has been attributed to alterations in platelet function and thrombocytopenia [175-177].

Elevation of pancreatic enzymes has been described, with nilotinib and ponatinib having the highest incidence. In the case of ponatinib, this adverse event is dose limiting in up to 7% of patients treated with the drug [152].

Elevation of liver enzymes has been reported with all TKIs, although the highest incidence occurs with nilotinib, bosutinib and ponatinib [178,179].

Competing Interests

The authors declare that they have no competing interests.

Acknowledgements

Medical writing support was provided by Pfizer.


References

  1. Spiers AS (1977) The clinical features of chronic granulocytic leukaemia. Clin Haematol 6: 77-95 [Google Scholar] [PubMed]
  2. Nowell PC (2007) Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 117: 2033-2035 [CrossRef] [Google Scholar] [PubMed]
  3. Rusconi F, Piazza R, Vagge E, Gambacorti-Passerini C (2014) Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opin Pharmacother 15: 701-710 [CrossRef] [Google Scholar] [PubMed]
  4. Bethelmie-Bryan B, Lord K, Holloway S, Khoury HJ (2014) Bosutinib treatment for Philadelphia chromosome-positive leukemias. Future Oncol 10: 179-185 [CrossRef] [Google Scholar] [PubMed]
  5. Zimmermann J, Caravatti G, Mett H, Meyer T, Muller M, et al. (1996) Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm (Weinheim) 329: 371-376 [CrossRef] [Google Scholar] [PubMed]
  6. Zimmermann S, Wels W, Froesch BA, Gerstmayer B, Stahel RA, et al. (1997) A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother 44: 1-9 [CrossRef] [Google Scholar] [PubMed]
  7. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, et al. (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94: 1765-1769 [CrossRef] [Google Scholar] [PubMed]
  8. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141 [CrossRef] [Google Scholar] [PubMed]
  9. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, et al. (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77: 1-11 [CrossRef] [Google Scholar] [PubMed]
  10. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D, et al. (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233: 212-214 [CrossRef] [Google Scholar] [PubMed]
  11. Van Etten RA, Jackson P, Baltimore D (1989) The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58: 669-678 [CrossRef] [Google Scholar] [PubMed]
  12. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL (1995) The Bcr- Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 92: 11746-11750 [CrossRef] [Google Scholar] [PubMed]
  13. Sawyers CL, McLaughlin J, Witte ON (1995) Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 181: 307-313 [CrossRef] [Google Scholar] [PubMed]
  14. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, et al. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151-6161 [CrossRef] [Google Scholar] [PubMed]
  15. Colicelli J (2010) ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 3: 6 [CrossRef] [Google Scholar] [PubMed]
  16. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13: 559-571 [Google Scholar]
  17. Khatri A, Wang J, Pendergast AM (2016) Multifunctional Abl kinases in health and disease. J Cell Sci 129: 9-16 [CrossRef] [Google Scholar] [PubMed]
  18. Moslehi JJ, Deininger M (2015) Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 33: 4210-4218 [CrossRef] [Google Scholar] [PubMed]
  19. Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, et al. (2014) Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 9: e92146 [CrossRef] [Google Scholar] [PubMed]
  20. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417 [CrossRef] [Google Scholar] [PubMed]
  21. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, et al. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26: 3358-3363 [CrossRef] [Google Scholar] [PubMed]
  22. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, et al. (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25: 481-496 [CrossRef] [Google Scholar] [PubMed]
  23. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, et al. (1990) Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66: 868-873 [CrossRef] [Google Scholar] [PubMed]
  24. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, et al. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101: 2368-2373 [CrossRef] [Google Scholar] [PubMed]
  25. Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739-3745 [CrossRef] [Google Scholar] [PubMed]
  26. Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, et al. (2012) Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87: 125-128 [CrossRef] [Google Scholar] [PubMed]
  27. Wehrle J, Pahl HL, von Bubnoff N (2014) Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 201: 99-107 [CrossRef] [Google Scholar] [PubMed]
  28. Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, et al. (2012) A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 69: 221-227 [CrossRef] [Google Scholar] [PubMed]
  29. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D, et al. (2011) Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 51: 1721-1727 [CrossRef] [Google Scholar] [PubMed]
  30. Abbas R, Boni J, Sonnichsen D (2015) Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metab Pers Ther 30: 57-63 [CrossRef] [Google Scholar] [PubMed]
  31. European Medicines Agency Sprycel (dasatinib): summary of product characteristics [View]
  32. Hsyu PH, Pignataro DS, Matschke K (2017) Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study. Clin Pharmacol Drug Dev 7: 373-381 [CrossRef] [Google Scholar] [PubMed]
  33. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, et al. (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44: 158-162 [CrossRef] [Google Scholar] [PubMed]
  34. Novartis Pharmaceuticals Corporation Tasigna® (nilotinib capsules): US prescribing information
  35. European Medicines Agency (19/02/2018) Iclusig (ponatinib): summary of product characteristics
  36. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, et al. (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 5: 85-97 [CrossRef] [Google Scholar] [PubMed]
  37. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551 [CrossRef] [Google Scholar] [PubMed]
  38. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, et al. (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942 [CrossRef] [Google Scholar] [PubMed]
  39. le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, et al. (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53: 313-323 [CrossRef] [Google Scholar] [PubMed]
  40. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, et al. (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367: 2075-2088 [CrossRef] [Google Scholar]
  41. Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, et al. (2009) Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63: 525-528 [CrossRef] [Google Scholar] [PubMed]
  42. Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D (2013) Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther 38: 440-444 [CrossRef] [Google Scholar] [PubMed]
  43. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, et al. (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87: 197-203 [CrossRef] [Google Scholar] [PubMed]
  44. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, et al. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92: 1641-1650 [CrossRef] [Google Scholar] [PubMed]
  45. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, et al. (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9: 625-632 [Google Scholar] [PubMed]
  46. European Medicines Agency Bosulif (bosutinib): summary of product characteristics [View]
  47. Kamath AV, Wang J, Lee FY, Marathe PH (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 61: 365-376 [CrossRef] [Google Scholar] [PubMed]
  48. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, et al. (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112: 1005-1012 [CrossRef] [Google Scholar] [PubMed]
  49. Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, et al. (2004) Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45: 695-698 [CrossRef] [Google Scholar] [PubMed]
  50. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, et al. (2002) Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 117: 623-625 [CrossRef] [Google Scholar] [PubMed]
  51. Abbas R, Chaudhary I, A. Hug B, Leister C, Burns J, et al. (2018) Mass Balance, Metabolic Disposition, Metabolite Characterization, and Pharmacokinetics of Oral 14C-Labeled Bosutinib in Healthy Subjects. In: 9th Triennial Meeting, International Society for the Study of Xenobiotics. Istambul, Turkey
  52. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, et al. (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36: 1357-1364 [CrossRef] [Google Scholar] [PubMed]
  53. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, et al. (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33: 1503-1512 [CrossRef] [Google Scholar] [PubMed]
  54. Kagan M, Tran P, Fischer V, Savage P, Smith T, et al. (2005) Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects. Blood 106: 4887-4887 [CrossRef] [Google Scholar]
  55. Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D, et al. (2013) Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol 71: 123-132 [CrossRef] [Google Scholar] [PubMed]
  56. Syed YY, McCormack PL, Plosker GL (2014) Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. BioDrugs 28: 107-120 [CrossRef] [Google Scholar] [PubMed]
  57. Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, et al. (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26: 563-569 [CrossRef] [Google Scholar] [PubMed]
  58. Health Canada Bosulif (bosutinib): Product Monograph
  59. Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, et al. (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26: 570-576 [CrossRef] [Google Scholar] [PubMed]
  60. Abrams P, Egorin M, Ramanathan R, Parise R, Lagattuta T, et al. (2004) Intrapatient consistency of imatinib pharmacokinetics (PK) in patients (pts) with advanced cancers. J Clin Oncol 22: 2081 [CrossRef] [Google Scholar]
  61. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, et al. (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 104: 2655-2660 [CrossRef] [Google Scholar] [PubMed]
  62. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, et al. (2008) Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112: 3348-3354 [CrossRef] [Google Scholar] [PubMed]
  63. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, et al. (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14: 3881-3888 [CrossRef] [Google Scholar] [PubMed]
  64. Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT, et al. (2013) Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos 41: 50-59 [CrossRef] [Google Scholar] [PubMed]
  65. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, et al. (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14: 5325-5331 [CrossRef] [Google Scholar] [PubMed]
  66. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44: 879-894 [CrossRef] [Google Scholar] [PubMed]
  67. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, et al. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21: 1267- 1275 [CrossRef] [Google Scholar] [PubMed]
  68. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, et al. (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65: 1485-1495 [CrossRef] [Google Scholar] [PubMed]
  69. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, et al. (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108: 697-704 [CrossRef] [Google Scholar] [PubMed]
  70. Melo JV (2006) Imatinib and ABCG2: who controls whom? Blood 108: 1116-1117 [CrossRef] [Google Scholar]
  71. Hamada A, Miyano H, Watanabe H, Saito H (2003) Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307: 824-828 [CrossRef] [Google Scholar] [PubMed]
  72. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, et al. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333-2337 [CrossRef] [Google Scholar] [PubMed]
  73. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, et al. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942 [CrossRef] [Google Scholar] [PubMed]
  74. Kompendium ch (2010) Switzerland: Compendium Suisse des médicaments
  75. Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D (2012) Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther 34: 2011-2019 [CrossRef] [Google Scholar] [PubMed]
  76. Hsyu PH, Pignataro DS, Matschke K (2017) Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. Eur J Clin Pharmacol 73: 49-56 [CrossRef] [Google Scholar] [PubMed]
  77. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, et al. (2010) Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116: 1582-1591 [CrossRef] [Google Scholar] [PubMed]
  78. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, et al. (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54: 290-294 [CrossRef] [Google Scholar] [PubMed]
  79. Cholongitas E, Pipili C, Katsogridakis K, Relos K, Dasenaki M, et al. (2008) Dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor. Cancer Chemother Pharmacol 61: 1083-1084 [CrossRef] [Google Scholar] [PubMed]
  80. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP, et al. (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78: 433-438 [CrossRef] [Google Scholar] [PubMed]
  81. Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, et al. (2005) Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 211: 363-365 [CrossRef] [Google Scholar] [PubMed]
  82. Zhou SF, Xue CC, Yu XQ, Li C, Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29: 687-710 [CrossRef] [Google Scholar] [PubMed]
  83. van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, et al. (2007) Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13: 7394-7400 [CrossRef] [Google Scholar] [PubMed]
  84. EMA Committee for Medicinal Products for Human Use (CHMP) (2013) Bosulif (bosutinibdasatinib): Assessment report
  85. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, et al. (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosomepositive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14: 352-359 [CrossRef] [Google Scholar] [PubMed]
  86. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ, et al. (2004) Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76: 323-329 [CrossRef] [Google Scholar] [PubMed]
  87. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, et al. (2004) The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24: 1508-1514 [CrossRef] [Google Scholar] [PubMed]
  88. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, et al. (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53: 102-106 [CrossRef] [Google Scholar] [PubMed]
  89. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, et al. (2004) Induction of imatinib metabolism by hypericum perforatum. Blood 104: 1229-1230 [CrossRef] [Google Scholar] [PubMed]
  90. Yin OQ, Gallagher N, Li A, Zhou W, Harrell R, et al. (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50: 188-194 [CrossRef] [Google Scholar] [PubMed]
  91. Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D (2013) Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol 53: 974-981 [CrossRef] [Google Scholar] [PubMed]
  92. Kajita T, Higashi Y, Imamura M, Maida C, Fujii Y, et al. (2006) Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. J Pharm Pharmacol 58: 997-1000 [CrossRef] [Google Scholar] [PubMed]
  93. Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, et al. (2007) INNO- 406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109: 306-314 [CrossRef] [Google Scholar] [PubMed]
  94. van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35: 692-706 [CrossRef] [Google Scholar] [PubMed]
  95. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, et al. (2003) Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89: 1855-1859 [CrossRef] [Google Scholar] [PubMed]
  96. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, et al. (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw Suppl 2: 1-29 [Google Scholar] [PubMed]
  97. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, et al. (2007) Imatinib-induced fatal acute liver failure. World J Gastroenterol 13: 6608-6111 [CrossRef] [Google Scholar] [PubMed]
  98. Rizack M, Hillman C (1998) The Medical Letter Handbook of Adverse Drug Interactions 1998. New Rochelle, NY: The Medical Letter Inc
  99. Hsyu PH, Pignataro DS, Matschke K (2017) Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects. Eur J Clin Pharmacol 73: 57-63 [CrossRef] [Google Scholar] [PubMed]
  100. Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, et al. (2007) Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176: 1243-1250 [CrossRef] [Google Scholar] [PubMed]
  101. Abbas R, Leister C, Sonnichsen D (2013) A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig 33: 589- 595 [CrossRef] [Google Scholar] [PubMed]
  102. Rassi FE, Khoury HJ (2013) Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia. Pharmgenomics Pers Med 6: 57-62 [CrossRef] [Google Scholar] [PubMed]
  103. Pfizer Inc (2017) BOSULIF® (bosutinib) tablets: US prescribing information. View
  104. Eley T, Luo FR, Agrawal S, Sanil A, Manning J, et al. (2009) Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 49: 700-709 [CrossRef] [Google Scholar] [PubMed]
  105. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, et al. (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65: 2577-2582 [CrossRef] [Google Scholar] [PubMed]
  106. DeAngelo DJ, Attar EC (2010) Use of dasatinib and nilotinib in imatinibresistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leuk Lymphoma 51: 363-375 [CrossRef] [Google Scholar] [PubMed]
  107. Xu Z, Cang S, Yang T, Liu D (2009) Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Hematol Rev 1: e4 [CrossRef] [Google Scholar] [PubMed]
  108. Hsyu PH, Mould DR, Abbas R, Amantea M (2014) Population pharmacokinetic and pharmacodynamic analysis of bosutinib. Drug Metab Pharmacokinet 29: 441-448 [CrossRef] [Google Scholar] [PubMed]
  109. Hsyu PH, Mould DR, Upton RN, Amantea M (2013) Pharmacokineticpharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol 71: 209-218 [CrossRef] [Google Scholar] [PubMed]
  110. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, et al. (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123: 494-500 [CrossRef] [Google Scholar] [PubMed]
  111. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, et al. (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25: 3908-3914 [CrossRef] [Google Scholar] [PubMed]
  112. Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, et al. (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 53: 305-325 [CrossRef] [Google Scholar] [PubMed]
  113. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, et al. (2010) Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 116: 377-386 [CrossRef] [Google Scholar] [PubMed]
  114. Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, et al. (2014) Multicenter phase II clinical trial of nilotinib for patients with imatinibresistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. Biomark Res 2: 6 [Google Scholar]
  115. Miura M (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38: 645-654 [CrossRef] [Google Scholar] [PubMed]
  116. Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, et al. (2011) Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol 93: 618-623 [CrossRef] [Google Scholar] [PubMed]
  117. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, et al. (2010) Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 101: 2186-2192 [CrossRef] [Google Scholar] [PubMed]
  118. Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, et al. (2012) Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 103: 1071-1078 [CrossRef] [Google Scholar] [PubMed]
  119. Miura M, Takahashi N (2013) Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients. Rinsho Ketsueki 54: 1720-1729 [Google Scholar] [PubMed]
  120. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, et al. (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111: 4022-4028 [CrossRef] [Google Scholar] [PubMed]
  121. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, et al. (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496-3499 [CrossRef] [Google Scholar] [PubMed]
  122. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, et al. (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28: 2381-2388 [CrossRef] [Google Scholar] [PubMed]
  123. Zhong JS, Meng FY, Xu D, Zhou HS, Dai M, et al. (2012) Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. Acta Haematol 127: 221-227 [CrossRef] [Google Scholar] [PubMed]
  124. Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, et al. (2012) Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica 97: 731-738 [CrossRef] [Google Scholar] [PubMed]
  125. White DL, Radich J, Soverini S, Saunders VA, Frede AK, et al. (2012) Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica 97: 907-914 [CrossRef] [Google Scholar] [PubMed]
  126. Li QB, Chen C, Chen ZC, Wang HX, Wu YL, et al. (2010) Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacol Sin 31: 999-1004 [CrossRef] [Google Scholar] [PubMed]
  127. Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, et al. (2011) Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 52: 1024-1029 [CrossRef] [Google Scholar] [PubMed]
  128. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, et al. (2009) A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit 31: 579-584 [CrossRef] [Google Scholar] [PubMed]
  129. Faber E, Friedecky D, Micova K, Rozmanova S, Divoka M, et al. (2012) Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol 91: 923-929 [CrossRef] [Google Scholar] [PubMed]
  130. Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, et al. (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33: 271-275 [CrossRef] [Google Scholar] [PubMed]
  131. Singh N, Kumar L, Meena R, Velpandian T (2009) Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65: 545-549 [CrossRef] [Google Scholar] [PubMed]
  132. Awidi A, Ayed AO, Bsoul N, Magablah A, Mefleh R, et al. (2010) Relationship of serum imatinib trough level and response in CML patients: long term follow-up. Leuk Res 34: 1573-1575 [CrossRef] [Google Scholar] [PubMed]
  133. Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, et al. (2012) Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 30: 200-205 [CrossRef] [Google Scholar] [PubMed]
  134. Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, et al. (2009) Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 89: 642-648 [CrossRef] [Google Scholar] [PubMed]
  135. Ieiri I (2012) Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 27: 85-105 [CrossRef] [Google Scholar] [PubMed]
  136. Mo W, Zhang JT (2012) Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3: 1-27 [Google Scholar] [PubMed]
  137. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, et al. (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101 [CrossRef] [Google Scholar] [PubMed]
  138. Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, et al. (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55: 731-737 [CrossRef] [Google Scholar] [PubMed]
  139. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, et al. (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14: 7102-7109 [CrossRef] [Google Scholar] [PubMed]
  140. Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, et al. (2013) A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica 98: 1407-1413 [CrossRef] [Google Scholar] [PubMed]
  141. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, et al. (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15: 4750-4758 [CrossRef] [Google Scholar] [PubMed]
  142. Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, et al. (2013) Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann Oncol 24: 756-760 [CrossRef] [Google Scholar] [PubMed]
  143. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, et al. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884 [CrossRef] [Google Scholar] [PubMed]
  144. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, et al. (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259 [CrossRef] [Google Scholar] [PubMed]
  145. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, et al. (1995) The genetic basis of the reduced expression of bilirubin UDPglucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333: 1171- 1175 [CrossRef] [Google Scholar] [PubMed]
  146. Fujita K, Sugiyama M, Akiyama Y, Ando Y, Sasaki Y (2011) The smallmolecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 67: 237-241 [CrossRef] [Google Scholar] [PubMed]
  147. Ai L, Zhu L, Yang L, Ge G, Cao Y, et al. (2014) Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica 44: 320-325 [CrossRef] [Google Scholar] [PubMed]
  148. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, et al. (2012) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68: 723-733 [CrossRef] [Google Scholar] [PubMed]
  149. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, et al. (2007) UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21: 2311-2315 [CrossRef] [Google Scholar] [PubMed]
  150. Abumiya M, Takahashi N, Niioka T, Kameoka Y, Fujishima N, et al. (2014) Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia. Drug Metab Pharmacokinet 29: 449-454 [CrossRef] [Google Scholar] [PubMed]
  151. Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, et al. (2013) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol 69: 813-823 [Google Scholar]
  152. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, et al. (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369: 1783-1796 [CrossRef] [Google Scholar] [PubMed]
  153. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, et al. (2016) Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res 48: 84-91 [CrossRef] [Google Scholar] [PubMed]
  154. Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, et al. (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168: 69-81 [CrossRef] [Google Scholar] [PubMed]
  155. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, et al. (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26: 2197-2203 [CrossRef] [Google Scholar] [PubMed]
  156. Atallah E, Durand JB, Kantarjian H, Cortes J (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110: 1233-1237 [CrossRef] [Google Scholar] [PubMed]
  157. Bristol-Myers Squibb Company (2017) Sprycel (dasatinib) [package insert]
  158. ARIAD Pharmaceuticals Inc (12/2017) ICLUSIG® (ponatinib) [package insert]
  159. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, et al. (2016) Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 34: 2333-2340 [CrossRef] [Google Scholar] [PubMed]
  160. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, et al. (2016) Longterm benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30: 1044-1054 [CrossRef] [Google Scholar] [PubMed]
  161. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, et al. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3540-3546 [CrossRef] [Google Scholar] [PubMed]
  162. Dahlen T, Edgren G, Lambe M, Hoglund M, Bjorkholm M, et al. (2016) Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study. Ann Intern Med 165: 161-166 [CrossRef] [Google Scholar] [PubMed]
  163. Breccia M, Loglisci G, Salaroli A, Serrao A, Alimena G (2012) Nilotinibmediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res 36: e66-67 [CrossRef] [Google Scholar] [PubMed]
  164. Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, et al. (2014) Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 99: 1197-1203 [CrossRef] [Google Scholar] [PubMed]
  165. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, et al. (2013) Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27: 1310-1315 [CrossRef] [Google Scholar] [PubMed]
  166. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, et al. (2016) Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17: 612-621 [CrossRef] [Google Scholar]
  167. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, et al. (2015) Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2: 376-383 [CrossRef] [Google Scholar] [PubMed]
  168. Rea D (2015) Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol 94 Suppl 2: 149-158 [CrossRef] [Google Scholar] [PubMed]
  169. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, et al. (2015) Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125: 901-906 [CrossRef] [Google Scholar] [PubMed]
  170. Ohnishi K, Sakai F, Kudoh S, Ohno R (2006) Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20: 1162-1164 [CrossRef] [Google Scholar] [PubMed]
  171. Peerzada MM, Spiro TP, Daw HA (2011) Pulmonary toxicities of tyrosine kinase inhibitors. Clin Adv Hematol Oncol 9: 824-836 [Google Scholar] [PubMed]
  172. Go SI, Lee WS, Lee GW, Kang JH, Kang MH, et al. (2013) Nilotinib-induced interstitial lung disease. Int J Hematol 98: 361-365 [CrossRef] [Google Scholar] [PubMed]
  173. Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, et al. (2015) Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90: 1060-1064 [CrossRef] [Google Scholar] [PubMed]
  174. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, et al. (2014) Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 123: 1309-1318 [CrossRef] [Google Scholar] [PubMed]
  175. Quintas-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, et al. (2009) Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115: 2482-2490 [CrossRef] [Google Scholar] [PubMed]
  176. Quintas-Cardama A, Han X, Kantarjian H, Cortes J (2009) Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114: 261-263 [CrossRef] [Google Scholar] [PubMed]
  177. Patodi N, Sagar N, Rudzki Z, Langman G, Sharma N (2012) Haemorrhagic colitis caused by dasatinib. Case Rep Hematol 2012: 417106 [CrossRef] [Google Scholar] [PubMed]
  178. Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385: 1447-1459
  179. Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36: 491-503 [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.